Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Bespak, SNBL sign global exclusive MOU for FDA-approved nasal dry powder delivery device
Licensing deal, drug delivery, nasal delivery, neurological, manufacturing - Read more

Zealand Pharma, Generate:Biomedicines partner on AI-designed obesity, metabolic drugs, up to $1.2B deal
Co-development, obesity, metabolic disease, AI/ML, milestone payments, royalties - Read more

Gilead Sciences snags equity stake in Vir Biotechnology for three T cell engagers, $135M upfront, $1.87B deal
Licensing deal, oncology, T cell engager, equity investment, milestone payments - Read more

Nxera Pharma, Synmosa Biopharma sign exclusive license and commercialization deal for QUVIVIQ across eight Asia-Pacific markets
Licensing deal, small molecule, insomnia, milestone payments, royalties, commercialization - Read more

Galderma's Nemluvio (nemolizumab) shows sustained three-year Ph3 responses in moderate to severe atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-31 inhibitor, prurigo nodularis - Read more

Verastem Oncology's (VS-7375) shows 50% objective response rate in Ph1/2 for KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma
Small molecule, cancer, KRAS inhibitor, pancreatic cancer, non-small cell lung cancer, colorectal cancer - Read more

Considering a continuous, automated approach to bioprocess and formulation analytics?

We can show you how - join CLADE and PAL System on October 21st to learn how to increase end-to-end analytical throughput and reduce human touchpoints across analytical workflows.

Ideal for: Biopharma analytical team leads, formulation and process development experts - register here.

Undecimal Bio launches with $18M seed financing to advance AI-powered siRNA delivery platform targeting renovascular disease
AI/ML platform, siRNA, RNA therapeutics, drug delivery, cardiovascular, preclinical - Read more

Soufflé Therapeutics raises $135M Series A to advance three cell-targeted RNA programs into clinic
RNA therapy, platform technology, rare disease, cardiovascular, oligonucleotide, preclinical - Read more

Altay Therapeutics raises $37M Series A to advance oral DUX4-targeting FSHD treatment
Rare disease, small molecule, neuromuscular, clinical-stage - Read more

United Therapeutics wins $380M patent settlement vs. Liquidia Technologies, forcing Yutrepia PH-ILD label removal
Small molecule, pulmonary hypertension, major transaction, competitive - Read more

Agilent Technologies acquires digital pathology software firm Proscia for $240M upfront
Digital pathology software, life sciences, major transaction, strategic - Read more

Galderma acquires Zo Skin Health for $1.5B, expanding medical-grade dermatology skincare portfolio
Dermatology skincare, dermatology, major transaction, strategic - Read more

Insulet Corporation launches Omnipod Discover data platform in full U.S. market release for Omnipod 5 users
Medical device, diabetes, competitive, operational - Read more

Rhythm Pharmaceuticals launches IMCIVREE in Japan as first approved therapy for acquired hypothalamic obesity
Small molecule, rare disease, revenue impact, regulatory - Read more

Sanofi avoids EU fine by committing to stop disparaging CSL Seqirus' rival flu vaccine
Vaccine, infectious disease, competitive, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Verdiva Bio discontinues Ph2 study of VRB-101 (oral ecnoglutide) targeting GLP-1 for overweight and obesity maintenance
Small molecule, metabolic, GLP-1 agonist, obesity, oral drug delivery, combination therapy - Read more

Johnson & Johnson Q3 earnings slip 4% as medtech underperforms; innovative medicines division carries results
Monoclonal antibody, oncology, financial, revenue impact - Read more

GSK cuts 1,200+ Belgium jobs across three sites amid $2.5B global restructuring plan
Vaccines, infectious disease, cost reduction, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here